Logo
x

Search category

Subscribe Now

ARAMIS study

Bayer Report Result of Nubeqa (darolutamide) + ADT in P-III ARAMIS Study for Non-Metastatic Castration-Resistant Prostate Cancer

Bayer Report Result of Nubeqa (darolutamide) + ADT in P-III ARAMIS Study for Non-Metastatic Castration-Resistant Prostate Cancer

  • January 30, 2020
Orion's Darolutamide Achieves 1EP in P-III ARAMIS study in Men with Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)

Orion's Darolutamide Achieves 1EP in P-III ARAMIS study in Men with Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)

  • October 25, 2018
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.